ASCO Virtual Scientific Program 2020
Professor Jessica Hassel presents findings from 'Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasised melanoma'
Data from profiling tumour associated antibodies in melanoma patients receiving immune checkpoint inhibitors was selected as a featured presentation at the American Society of Clinical Oncology 2020 (ASCO) Virtual Scientific Programme.
The featured presentation reviewed data assessing samples from patients receiving either Pembrolizumab, Ipilimumab, Nivolumab monotherapy, or combination therapy of Ipilimumab and Nivolumab, which have been analysed on Oncimmune's proprietary biomarker discovery engine, SeroTag®. The data identified that autoantibodies have a role in predicting clinical outcomes or immune-related adverse events ("irAEs").
This was the first time that the clinical utility of autoantibodies were presented at this prestigious international cancer research conference.
Oncimmune is at the forefront in understanding the utility of autoantibodies in a clinical setting. This exciting study demonstrates the strides we have made in unlocking the potential of our autoantibody platform to improve patient outcomes.
Dr Adam M Hill, CEO